ELATEC Strengthens Global Presence with Regional Hub in Dubai
23.1.2025 12:23:08 CET | news aktuell GmbH | Press release
Puchheim, January 23, 2025 – ELATEC, a leading global provider of user authentication and identification solutions, is beginning 2025 with a significant step forward in its global expansion strategy: the launch of its new office in Dubai. Operating under the name ELATEC Middle East Trading FZE, this new location will serve as a dedicated hub to support the company’s growing customer base and partners across the Middle East. The operations, led by Managing Director Carsten Hoersch, are set to drive innovative, secure, and tailored access control solutions in the region.
A Strategic Milestone in the Middle East
Gerhard Burits, CEO of the ELATEC Group, emphasized the strategic importance of this expansion: “Our new presence in the GCC (Gulf Cooperation Council) demonstrates our commitment to strengthening relationships with regional partners and addressing market-specific needs. This move aligns seamlessly with our mission to provide secure, flexible, and future-ready solutions. The Dubai office is a vital addition to our global network and will act as a springboard for further growth in this dynamic region.”
The Middle East is a region of rapid development and innovation, and ELATEC’s new office demonstrates the company’s commitment to identification technologies that empower customers to deliver advanced solutions to their markets.
Driving Localized Solutions and Collaboration
With the launch of ELATEC Middle East Trading FZE, the company aims to foster closer collaboration with OEMs, system integrators, distributors, and other local stakeholders. This local presence allows ELATEC to address specific market demands and offer enhanced customer support and faster response times.
Carsten Hoersch, Managing Director of ELATEC Middle East Trading FZE, shared his vision for the new office: “Establishing a local hub in the United Arab Emirates enables us to work hand-in-hand with our partners and customers, developing innovative solutions that add real value to their businesses. Our focus is on building trust, delivering top-tier support, and driving advancements in secure and seamless access technology tailored to the region’s unique requirements.”
About ELATEC
ELATEC is a leading global provider of user authentication and identification solutions. Together with its global partners, the company develops innovative and future-proof access systems. Combining pioneering universal readers, advanced authentication software, and world-class service and support, ELATEC delivers secure, flexible solutions that transform access management—from physical access control to digital access management, machine authentication, secure printing, EV charging, and more. ELATEC’s comprehensive portfolio of multi-technology readers supports more than 60 transponder technologies (including LF and HF RFID, NFC, and BLE) and is remotely configurable and updatable, ensuring seamless interoperability and adaptability to evolving market needs. ELATEC collaborates with OEMs, integrators, and organizations to design customized access solutions that enhance security, improve user convenience, and simplify management. Founded in 1988 and headquartered in Munich, Germany, ELATEC is represented at 19 locations worldwide. For more information, visit www.elatec.com.
Suited Pictures (Copyright ELATEC): https://pixx.elatec.com/share/1737467969oJ4Vn0qvwbkLcf
Press contact ELATEC GmbH:
Anna Vanessa Evertz
Zeppelinstraße 1
82178 Puchheim
Germany
Tel.: +49895529961-135
E-Mail: a.evertz@elatec.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
They’re really going for it: emporia launches the first 5G smartphone with a screen warranty15.7.2026 08:40:22 CEST | Press release
Better safe than sorry: the emporiaSMART.8 with Smartcover and rubber protectors
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 12:28:23 CEST | Press release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom